Dual-antibody Modified PLGA Nanofibers for Specific Capture of Epithelial and Mesenchymal CTCs.

CTC detection has great potential to provide crucial clinical information for early cancer diagnosis, patient prognosis, personalized therapy, and cancer progress monitoring etc. It has been proved that the disease progress is associated with an increase in mesenchymal CTCs, while most mature techniques have been developed based on epithelial CTC detection. In present work, a dual-antibody nanointerface against EpCAM and N-Cadherin was developed to capture epithelial CTCs as well as mesenchymal CTCs from blood samples. A uniform poly-(lactic-co-glycolic acid) (PLGA) nanofiber substrate was fabricated by electrospinning to provide a platform for cell capture (i.e., MCF-7 and GIST882 cells), modified with BSA and dual antibodies. Our results showed the dual-antibody substrates exhibited an improved capture efficiency of target cells compared to the mono-antibody ones, revealing potential application of the dual-antibody PLGA nanofibers for efficient capture of epithelial and mesenchymal CTCs in clinic.